Windfar-L Tablet contains Levocetirizine 5mg and Montelukast 10mg, combining an antihistamine and a leukotriene receptor antagonist to provide effective relief from allergic conditions. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, reducing symptoms such as sneezing, nasal congestion, rhinorrhea, and itching associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks the action of leukotrienes, inflammatory mediators involved in bronchoconstriction, mucus production, and airway edema, thereby improving respiratory function in conditions like asthma and allergic rhinitis. The combination in Windfar-L Tablet is indicated for the management of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct in asthma therapy to control symptoms and improve quality of life. It is generally well tolerated, with common adverse effects including headache, fatigue, and gastrointestinal disturbances. Windfar-L should be used under medical supervision, especially in patients with hepatic or renal impairment, and caution is advised in those with a history of neuropsychiatric events. The dosing regimen typically involves once-daily administration, optimizing patient compliance. This combination therapy offers a comprehensive approach to allergy management by targeting multiple inflammatory pathways.